[PDF][PDF] T cell cancer therapy requires CD40-CD40L activation of tumor necrosis factor and inducible nitric-oxide-synthase-producing dendritic cells

I Marigo, S Zilio, G Desantis, B Mlecnik, AHR Agnellini… - Cancer cell, 2016 - cell.com
I Marigo, S Zilio, G Desantis, B Mlecnik, AHR Agnellini, S Ugel, MS Sasso, JE Qualls
Cancer cell, 2016cell.com
Effective cancer immunotherapy requires overcoming immunosuppressive tumor
microenvironments. We found that local nitric oxide (NO) production by tumor-infiltrating
myeloid cells is important for adoptively transferred CD8+ cytotoxic T cells to destroy tumors.
These myeloid cells are phenotypically similar to inducible nitric oxide synthase (NOS2)-and
tumor necrosis factor (TNF)-producing dendritic cells (DC), or Tip-DCs. Depletion of
immunosuppressive, colony stimulating factor 1 receptor (CSF-1R)-dependent arginase 1+ …
Summary
Effective cancer immunotherapy requires overcoming immunosuppressive tumor microenvironments. We found that local nitric oxide (NO) production by tumor-infiltrating myeloid cells is important for adoptively transferred CD8+ cytotoxic T cells to destroy tumors. These myeloid cells are phenotypically similar to inducible nitric oxide synthase (NOS2)- and tumor necrosis factor (TNF)-producing dendritic cells (DC), or Tip-DCs. Depletion of immunosuppressive, colony stimulating factor 1 receptor (CSF-1R)-dependent arginase 1+ myeloid cells enhanced NO-dependent tumor killing. Tumor elimination via NOS2 required the CD40-CD40L pathway. We also uncovered a strong correlation between survival of colorectal cancer patients and NOS2, CD40, and TNF expression in their tumors. Our results identify a network of pro-tumor factors that can be targeted to boost cancer immunotherapies.
cell.com